Linker Information
General Information of This Linker
| Linker ID |
LIN0KJCUA
|
|||||
|---|---|---|---|---|---|---|
| Linker Name |
KR1020250002133A Trastuzumab-C-117 Linker
|
|||||
| Linker Type |
Cathepsin-cleavable linker
|
|||||
| Antibody-Linker Relation |
Cleavable
|
|||||
| Structure |
|
|||||
| Formula |
C71H111N13O19S
|
|||||
| Isosmiles |
CC([C@H](NC([C@@H](NC(CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCN1CCC(CC1)C2=CC3=NC(N)=C(N=C4CCCC)C(N4)=C3S2)=O)CCCCNC(CCN5C(C=CC5=O)=O)=O)=O)C(N[C@@H](CCCNC(N)=O)C(NC6=CC=C(CO)C=C6)=O)=O)C
|
|||||
| InChI |
InChI=1S/C71H111N13O19S/c1-4-5-11-58-80-64-65(81-58)67(72)78-56-48-57(104-66(56)64)52-18-24-83(25-19-52)27-29-95-31-33-97-35-37-99-39-41-101-43-45-103-47-46-102-44-42-100-40-38-98-36-34-96-32-30-94-28-21-60(87)77-54(9-6-7-22-74-59(86)20-26-84-61(88)16-17-62(84)89)69(91)82-63(50(2)3)70(92)79-55(10-8-23-75-71(73)93)68(90)76-53-14-12-51(49-85)13-15-53/h12-17,48,50,52,54-55,63,85H,4-11,18-47,49H2,1-3H3,(H2,72,78)(H,74,86)(H,76,90)(H,77,87)(H,79,92)(H,80,81)(H,82,91)(H3,73,75,93)/t54-,55-,63-/m0/s1
|
|||||
| InChIKey |
JKOLKDRXBDPFHM-NXELZZONSA-N
|
|||||
| Pharmaceutical Properties |
Molecule Weight
|
1482.808
|
Polar area
|
421.36
|
||
|
Complexity
|
3092.130849
|
xlogp Value
|
3.1244
|
|||
|
Heavy Count
|
104
|
Rot Bonds
|
58
|
|||
|
Hbond acc
|
24
|
Hbond Donor
|
10
|
|||
Each Antibody-drug Conjugate Related to This Linker
Full Information of The Activity Data of The ADC(s) Related to This Linker
Trastuzumab-C-17 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.014 nM
|
High HER2 expression (HER19 +++) | ||
| Method Description |
Trastuzumab-C-17 was tested in HCC1954,80ul,18ᆬh
|
||||
| In Vitro Model | Breast ductal carcinoma | HCC1954 cells | CVCL_1259 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.32 nM
|
High HER2 expression (HER19 +++) | ||
| Method Description |
Trastuzumab-C-17 was tested in NCI-N87,80ul,18ᆬh
|
||||
| In Vitro Model | Gastric tubular adenocarcinoma | NCI-N87 cells | CVCL_1603 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
3.39 nM
|
High HER2 expression (HER19 +++) | ||
| Method Description |
Trastuzumab-C-17 was tested in HCC1954 and PBMC,50ul,24h
|
||||
| In Vitro Model | Breast ductal carcinoma | HCC1954 cells | CVCL_1259 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Emax (TNF-a) |
788.8 pg/mL
|
High HER2 expression (HER19 +++) | ||
| Method Description |
Trastuzumab-C-17 was tested in HCC1954 and PBMC,50ul,24h
|
||||
| In Vitro Model | Breast ductal carcinoma | HCC1954 cells | CVCL_1259 | ||